Drug Regulations, Acts, and Legal Framework

Pharmacovigilance and Post-Marketing Surveillance

Pharmacovigilance is crucial for post-marketing drug surveillance, ensuring the safety and efficacy of medications through legal frameworks and regulations.

6/7/20254 min read67 views
loved it
normalintermediatePharmacology
Pharmacovigilance and Post-Marketing Surveillance

Drug Regulations, Acts, and Legal Framework

Pharmacovigilance and Post-Marketing Surveillance

Ensuring drug safety is a fundamental aspect of healthcare and regulatory agencies worldwide. The process does not stop after drug approval; continuous monitoring, known as pharmacovigilance, is essential to track adverse effects and safeguard public health.

What is Pharmacovigilance?

Pharmacovigilance refers to the activities aimed at detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems. Regulatory bodies like the FDA, EMA, and CDSCO require pharmaceutical companies to report adverse drug reactions (ADRs).

Key Regulations and Acts

  • FDA Drug Safety Regulations: The US FDA monitors drugs post-approval through the MedWatch program.
  • EMA Guidelines: The European Medicines Agency (EMA) enforces the EudraVigilance system.
  • India's Pharmacovigilance Programme: The Pharmacovigilance Programme of India (PvPI) is responsible for ADR reporting.

Post-Marketing Surveillance Strategies

Post-marketing surveillance involves the systematic collection and analysis of data related to drug effects in large populations.

  • Spontaneous ADR Reporting Systems
  • Observational Studies
  • Electronic Health Record Monitoring
  • Prescription Event Monitoring

Conclusion

Pharmacovigilance ensures continuous monitoring of drug safety, protecting patients from unforeseen risks. Regulatory frameworks must evolve to enhance drug safety surveillance.

Tags

#Pharmacovigilance#Drug Safety#Post-Marketing Surveillance#FDA#EMA#PvPI

0 people loved it

Recommended Reads

Explore related articles that might interest you

Drug Development Process and Clinical Trial Phases
17
13%

Drug Development Process and Clinical Trial Phases

Read more →
17
Definition, classification, and management of adverse drug reactions (ADR)
10
12%

Definition, classification, and management of adverse drug reactions (ADR)

Read more →
10
Principles of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting Systems
14
12%

Principles of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting Systems

Read more →
14
Principles of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting Systems
7
12%

Principles of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting Systems

Read more →
7
Principles of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting Systems
39
12%

Principles of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting Systems

Read more →
39
Drug Regulations, Acts, and Legal Framework
46
12%

Drug Regulations, Acts, and Legal Framework

Read more →
46
Drug Regulations, Acts, and Legal Framework
42
12%

Drug Regulations, Acts, and Legal Framework

Read more →
42
© 2025 MedGloss. All rights reserved.